



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / سامية زكى يوسف

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد





Association Between *GLIS3* rs7020673 Polymorphism and Type 2 Diabetes Mellitus among Egyptian Population

Thesis

*Submitted for Partial Fulfillment of M.D. Degree
in Clinical Pathology*

By

Lubna Ezz Eldin Mohamed

*M.B., B.Ch, M.Sc in Clinical Pathology
Faculty of Medicine, Ain Shams University*

Under Supervision of

Prof. Eman Saleh El Hadidi

*Professor of Clinical Pathology
Faculty of Medicine - Ain Shams University*

Prof. Wessam El Sayed Saad

*Professor of Clinical Pathology
Faculty of Medicine - Ain Shams University*

Prof. Maram Mohmed Maher Mahdy

*Professor of Internal Medicine and Endocrinology
Faculty of Medicine - Ain Shams University*

Assist. Prof. Walaa Ahmed Yousry

*Assistant Professor of Clinical Pathology
Faculty of Medicine - Ain shams University*

Faculty of Medicine
Ain Shams University

2022

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العليم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I would like to express my indebtedness and deepest gratitude to **Prof. Eman Saleh El Hadidi**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, **put peace on her soul**, for her valuable advice, guidance and constructive criticism, also for the invaluable assistance and efforts she devoted in the supervision of this study.*

*I'll never forget, how co-operative was **Prof. Wessam El Sayed Saad**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, also she was encouraging all the time. It is honorable to be supervised by her.*

*I would like also, to express my great thanks to **Prof. Maram Mohamed Maher Mahdy**, Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, her valuable advises and continuous support facilitated completing this work.*

*I would like also, to express my great thanks to **Assist. Prof. Walaa Ahmed Yousry**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, her valuable advises and continuous support facilitated completing this work.*

I would like to express my appreciation and gratitude to all my family, especially my caring and loving parents who enlighten my life.

*Finally, I want to thank **my husband**, his support meant a lot to me. I want to thank him for helping me and for his patience all through the way.*

I would like to thank all the staff members of the Clinical Pathology department.

Lubna Ezz Eldin Mohamed

List of Contents

Title	Page No.
List of Abbreviations	i
List of Tables.....	v
List of Figures	vi
Introduction	1
Aim of the Work.....	3
Review of Literature	
I: Type 2 Diabetes Mellitus	4
A. Epidemiology of T2DM	4
B. Risk Factors for T2DM	5
C. Pathophysiology of T2DM	10
D. Complications of T2DM.....	13
E. Diagnosis of T2DM	16
II: GLI-Similar 3	24
A. <i>GLIS3</i> Gene	24
B. Structure of the GLIS3 protein.....	25
C. Mechanism of Action of GLIS3 Protein	27
D. Regulation of GLIS3 Protein.....	29
E. Role of GLIS3 Protein in Diabetes.....	32
F. <i>GLIS3</i> Gene Polymorphism in Diabetes.....	36
G. Other Diseases Associated with <i>GLIS3</i> Gene Polymorphism .	37
H. Methods of Assay of <i>GLIS3</i> rs7020673 Polymorphism	41
Subjects and Methods.....	47
Results.....	69
Discussion	77
Summary and Conclusion	86
Recommendations.....	88
References	89
Arabic Summary.....	١

List of Abbreviations

Abb.	Full term
2-h PG	2-h Plasma Glucose
ADA	American Diabetes Association
ALL.....	Acute Lymphoblastic Leukaemia
AMKL.....	Acute Megakaryoblastic Leukaemia
BCAR1.....	Breast cancer antiestrogen resistance 1
BIM.....	Bcl-2 interacting mediator of cell death
BIM S	Bcl-2 interacting mediator of cell death Short isoform
BMI.....	Body Mass Index
C2H2	Cys2His2
CBD	C-terminal Binding Protein
CCND2	Cyclin D2
CDK5	Cyclin Kinase 5
CDKAL1	CDK5 regulatory subunit associated protein 1-like 1
CI.....	Confidence interval
CKD.....	Chronic kidney disease
CLIA.....	Chemiluminescence immunoassay
COBL.....	Cordon-Bleu WH2 Repeat Protein
CVD	Cardiovascular disease
DBD.....	DNA-binding Domain
DCCT.....	Diabetes Control and Complications Trial
DM.....	Diabetes mellitus
E1	Ubiquitin-activating enzyme
E2	Ubiquitin-conjugating enzyme
E3	Ubiquitin–protein ligase
ELISA.....	Enzyme-linked immunosorbent assay
ER.....	Endoplasmic reticulum
ESRD.....	End-stage renal disease
FAM.....	Fluorescein amidites
FPG	Fasting Plasma Glucose
FGF18	Fibroblast growth factor 18
FOXA2.....	Forkhead box A2
FT4	Free thyroxine

List of Abbreviations *cont...*

Abb.	Full term
GA.....	Glycated albumin
GDM	Gestational diabetes mellitus
GLIS3	Gli similar 3
GLIS3-REs	GLIS3-response elements
GLISBS	GLIS-binding sites
GWAS.....	Genome-wide association studies
H.....	Kruskal-Wallis Test
Hb A1c.....	Glycated hemoglobin A1c
HCC.....	Hepatocellular carcinoma
Hh.....	Hedgehog
HLA	Human Leukocyte Antigen
HNF1 β	Hepatocyte nuclear factor 1 β
HNF6.....	Hepatocyte nuclear factor 6
HOMA	Homeostatic model assessment
HPLC.....	High-performance liquid chromatography
HPLC-UV	High performance liquid chromatography coupled with ultraviolet detection
HRP	Streptavidin-horse radish peroxidase
HS.....	Highly-significant difference
HTN.....	Hypertension
IA.....	Islet autoimmunity
IDF	International Diabetes Federation
IFG	Impaired fasting glucose
IGT	Impaired glucose tolerance
Ins2.....	Insulin gene
IR.....	Insulin resistance
KDIGO	Kidney Disease: Improving Global Outcomes
LC-MS/MS.....	Liquid chromatography with tandem mass spectrometry
MTNR1B	Melatonin receptor 1B
NDH	Neonatal diabetes and congenital hypothyroidism
NFQ.....	Non-fluorescent quencher
NGN3	Neurogenin 3

List of Abbreviations *cont...*

Abb.	Full term
NGS	Next generation sequencing
NGSP.....	National Glycohemoglobin Standardization Program
NRD.....	N-terminal Repressive Domain
NS.....	Non-significant difference
OGTT.....	Oral glucose tolerance test
OR.....	Odds ratio
P –value.....	Probability
PCR-RFLP.....	Polymerase chain reaction-restriction fragment length polymorphism
PDX1	Pancreatic duodenal homeobox 1
PIAS4	Protein Inhibitor of Activated STAT 4
PKC	Protein Kinase C
PPARG	Peroxisome proliferator-activated receptor-gamma
PPxY.....	Proline- Proline-x-Tyrosin
Prox1	Prospero homeobox protein 1
Ptch	Protein patched homolog
qPCR	Quantitative polymerase chain reaction
RCC	Renal cell carcinoma
real-time PCR	Real-time polymerase chain reaction
RIA	Radioimmunoassay
ROS	Reactive oxygen species
S.....	Significant difference
Shh	Sonic Hedgehog
SMAD2.....	Suppressor of Mothers against Decapentaplegic
Smo.....	Smoothened
SNP	Single nucleotide polymorphism
SNPs.....	Single nucleotide polymorphisms
SRP55.....	Splicing factor protein 55
SUFU.....	Suppressor of Fused
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus

List of Abbreviations *cont...*

Abb.	Full term
TAD	Transactivation Domain
TCF7L2	Transcription factor 7-like 2
TGF β	Transforming growth factor β
TMB.....	Tetra methyl benzidine
TSH	Thyroid-stimulating hormone
VIC	Victoria blue dye 2`-chloro-7` phenyl-1, 4- dichloro-6- carboxy- fluorescein
WFS1	Wolfram syndrome 1
WHO.....	World Health Organization
WNT	Wingless related integration site
WWTR1	WW domain containing transcription regulator 1
X ²	Chi-Square Test
Z.....	Wilcoxon`s Rank-Sum Test
ZF	Zinc finger

List of Tables

Table No.	Title	Page No.
Table 1:	Examples of Genetic Loci Associated with T2DM and their Mechanisms	9
Table 2:	Criteria of Prediabetes	17
Table 3:	Diagnostic Criteria for Diabetes	17
Table 4:	Thermal Cycling Protocol	59
Table 5:	Relation between Fluorescence Signals and Sequences in a Sample	60
Table 6:	Reagents of Cycle Sequencing	62
Table 7:	Sequencing Thermal Profile	63
Table 8:	Descriptive and Comparative Statistics of the various Studied Parameters between Diabetic Patients (Group I) versus Healthy Controls (Group II) using Wilcoxon`s Rank-Sum Test.....	71
Table 9:	Descriptive and Comparative Statistics of the Genotypic Frequency of <i>GLIS3</i> rs7020673 C>G Polymorphism in Diabetic Patients (Group I) versus Healthy Controls (Group II) using Chi-Square Test	72
Table 10:	Association Analysis of <i>GLIS3</i> rs7020673 Genotypes in (Group I) versus (Group II).....	73
Table 11:	Descriptive and Comparative Statistics Between Diabetic Patients (Group I) versus Healthy Controls (Group II) Regarding Allele Frequencies of <i>GLIS3</i> rs7020673 Polymorphism Using Chi-Square Test	74
Table 12:	Comparative Statistics between the <i>GLIS3</i> rs7020673 Genotypes among Diabetic Patients in Respect to Different Demographic and Laboratory Findings using Kruskal-Wallis Test.....	75

List of Figures

Fig. No.	Title	Page No.
Figure 1:	β -Cell function and mass changes over the time course of type 2 diabetes mellitus.....	11
Figure 2:	Prognosis of CKD by GFR and albuminuria categories	23
Figure 3:	Human <i>GLIS3</i> gene and protein structures	25
Figure 4:	<i>GLIS3</i> functional domains and interacting proteins.....	27
Figure 5:	Sonic Hedgehog (Shh) signaling pathway	30
Figure 6:	Molecular actions of <i>GLIS3</i> in type 2 diabetes ...	33
Figure 7:	Schematic representation of the disease spectrum caused by <i>GLIS</i> genetic alteration.....	38
Figure 8:	Schematic diagram of PCR-RFLP approach.....	42
Figure 9:	How stuff works: NGS an overview	45
Figure 10:	Genomic DNA extraction procedure	56
Figure 11:	Illustration of the principle of the real-Time PCR allelic discrimination through different fluorescence emission	57
Figure 12:	Steps of Sanger Sequencing	61
Figure 13a:	Detection of <i>GLIS3</i> homozygous G\G mutation using Sanger Sequencing	64
Figure 13b:	Detection of <i>GLIS3</i> heterogenous G\C mutation using Sanger Sequencing	66
Figure 14:	Genotype frequencies of <i>GLIS3</i> rs7020673 polymorphism in diabetic patients versus healthy controls.....	72
Figure 15:	<i>GLIS3</i> rs7020673 genotypes in respect to HBA1c percentage	76

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a heterogeneous metabolic disease characterized by glucose intolerance, which seems to result from the combined effects of insulin resistance and a failure of the pancreatic β -cells to compensate for the increased demand of insulin (*Alexandra et al., 2017*).

Type 2 diabetes mellitus (T2DM) represents a global major healthcare burden. According to the International Diabetes Federation (IDF), Egypt is in the World's 8th place in terms of diabetes incidence, affecting up to 8.2 million people. By the year 2045, Egypt is expected to be in the 6th place, with about 16.7 million diabetic patients and will represent the highest incidence in the Middle East and North Africa region. Therefore, it is crucial to understand the mechanisms that contribute to the pathogenesis of DM (*International Diabetes Federation, 2017*).

Type 2 diabetes mellitus (T2DM) is a multi-factorial disease, genetic and environmental factors as well as life style have been considered as major risk factors in the development of T2DM (*Hasan et al., 2018*). However, it is supposed that the environmental factors and life style changes may lead to T2DM only in the presence of predisposing genetic factors to the disease. Great efforts have been made to identify the different genes associated with the risk of development of T2DM (*Prabhanjan et al., 2016*).

The GLI-similar 3 (*GLIS3*) gene codes for a Krüppel-like zinc finger transcription factor that is located in a nuclear compartment of the cell and in the Golgi complex and is highly expressed in beta cells. It controls gene transcription through Glis3-binding sites (GLISBS) in regulatory regions of the target genes (*Guilherme et al., 2017*).

Growing evidence indicates that GLIS3 plays a critical role in pancreatic cell lineage specification, particularly in the development of mature beta cells. GLIS3 is also important to beta cell mass maintenance and regulation of insulin expression in adults (*Guilherme et al., 2017*). GLIS3 may function as a cell-type-dependent trans activator or repressor and may protect pancreatic β cells against apoptosis (*Wen and Yang, 2017*).

Single nucleotide polymorphism (SNP) is a variation at a single position in a DNA sequence among individuals (*Matsuda, 2017*). *GLIS3* (rs7020763) which shows reduced GLIS3 expression was found to modulate the alternative splicing of the pro-apoptotic protein, promoting the expression of apoptosis of the β cell and β cell death. These data suggest that proper GLIS3 expression could be required for β cell survival (*Wen and Yang, 2017*).

AIM OF THE WORK

The aim of the present study is to investigate the potential association between the *GLIS3* (rs7020763) gene polymorphism and type 2 diabetes mellitus and its impact on glycemic control among Egyptian population.

TYPE 2 DIABETES MELLITUS

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both (*Goyal and Jialal, 2022*).

A. Epidemiology of T2DM:

According to the International Diabetes Federation (IDF), in 2021, diabetes caused 6.7 million deaths; and 537 million adults aged between 20 and 79 years old were living with diabetes, a number that will likely rise up to 783 million by 2045. (*International Diabetes Federation, 2021*). The World Health Organization (WHO) Global report on diabetes shows that the number of adults living with diabetes has almost quadrupled since 1980 to 422 million adults (*WHO, 2019*).

Egypt is in the world's tenth place in terms of diabetes incidence, affecting up to 10.9 million people in 2021. By the year 2045, Egypt is expected to be in the ninth place, with about 20 million diabetic patients, due to the rapidly increasing and aging population, which will be one of the highest incidence rates in the Middle East and North Africa regions. It was estimated that there were about 6.8 million undiagnosed diabetic cases in Egypt. DM represents a huge economic burden, in 2021; the IDF estimated the total healthcare expenditure worldwide on diabetes to reach 966 billion dollars, meanwhile in Egypt, the healthcare